Nanomedicine in a world of immunotherapy

Dr. Shiladitya Sengupta

Abstract:
What are the key factors that results in clinical success of Nanomedicines. What are the challenges that lie in the clinical translation of Nanomedicine. Where does Nanomedicine stand in cancer management in the fast changing world of emerging immune-based therapies. Are there challenges in Immunooncology that can be addressed by nanotechnology. This talk shall address some of these hot questions in Nanomedicines.

Biography:
Dr. Sengupta is the assistant professor of medicine and HST at Harvard Medical School and Harvard-MIT Division of HST. He has been recognized as one of the top 35 innovators of the world under 35 (TR35 award), by Technology Review magazine. He has been awarded the Era of Hope Scholar award by the Department of Defense, ta Coulter Foundation career award, and is a TED fellow. He was a Nehru Scholar at Trinity College, University of Cambridge, and is one of the youngest recipients of the Shakuntala Amir Chand Prize from the Indian Council of Medical Research. Dr. Sengupta is a serial entrepreneur, and has cofounded Cerulean Pharmaceuticals, Vyome Bioscences, Invictus Oncology, Akamara Therapeutics and Mitra Biotech.

For any inquiries, contact Prof. Ali Khademhosseini at khademh@ucla.edu